Keywords: Deuterium, Cancer, Preclinical
Motivation: Diffuse midline gliomas (DMGs) are devastating pediatric brain tumors. Although MRI is the mainstay for DMG imaging, it does not reliably report on response to therapy.
Goal(s): The goal of this study was to assess the utility of deuterium metabolic imaging for DMGs.
Approach: To this end, we interrogated [6,6’-2H]-glucose metabolism in patient-derived and syngeneic models.
Results: [6,6’-2H]-glucose enables non-invasive visualization of the metabolically active tumor lesion in mice bearing intracranial DMGs. Importantly, [6,6’-2H]-glucose provides an early readout of response to targeted therapy in vivo. Collectively, our studies highlight the potential of [6,6’-2H]-glucose for imaging tumor burden and response to therapy in DMGs.
Impact: Diffuse midline gliomas are deadly childhood brain tumors. Using clinically relevant patient-derived and murine tumor models, we show that deuterium metabolic imaging using [6,6’-2H]-glucose enables non-invasive assessment of tumor burden and early response to therapy in diffuse midline gliomas.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords